tradingkey.logo
tradingkey.logo
Search

Oncolytics Biotech® Reports Durable Responses In Second-Line Ras-Mutant Mss Colorectal Cancer

ReutersMay 4, 2026 1:09 PM
facebooktwitterlinkedin
View all comments0

- Oncolytics Biotech Inc ONCY.O:

  • ONCOLYTICS BIOTECH® REPORTS DURABLE RESPONSES IN SECOND-LINE RAS-MUTANT MSS COLORECTAL CANCER

  • ONCOLYTICS BIOTECH INC - ENGAGED WITH FDA ON ACCELERATED APPROVAL PATHWAY FOR 2L RAS-MUTANT MSS MCRC

  • ONCOLYTICS BIOTECH INC - PELAEOREOREP COMBINATION SHOWS 19.5-MONTH MEDIAN DURATION OF RESPONSE IN 2L KRAS-MUTANT MSS MCRC

  • ONCOLYTICS BIOTECH INC - 2L KRAS-MUTANT MSS MCRC DEMONSTRATES 3-4X IMPROVEMENT IN DURATION OF RESPONSE VERSUS. HISTORICAL 4-6 MONTH BENCHMARK

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Comments (0)

Click the $ button, enter the symbol, and select to link a stock, ETF, or other ticker.

0/500
Commenting Guidelines
Loading...

Recommended Articles

Tradingkey
KeyAI